Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, GC AND SECRETARY | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 4,619 |
Ending reported balance
After 2026-03-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-27 · Tax withholding · Disposed 14,850 · Balance 23,287 Row 2 · 2026-03-02 · Sale · Disposed 5,777 · Balance 17,510 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-03-02 · Sale · Disposed 10,291 · Balance 7,219 F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-03-02 · Sale · Disposed 2,600 · Balance 4,619 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2024 Filed Feb 6, 2024 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Disposition to issuerCommon Stock, $0.01 par value | 2,919 | $170.00 | $496,230.00 |
DisclosureSEC source: 0001415889-24-002828 · form4-02062024_050202.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,377 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on February 14, 2023. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,919 | $144.54 | $421,912.26 |
DisclosureSEC source: 0001415889-24-002828 · form4-02062024_050202.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,296 Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 3,520 | $105.92 Strike: $105.92 | $372,838.40 |
DisclosureSEC source: 0001415889-23-006300 · form4-04052023_050401.xml · derivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,520 Underlying: Common Stock · 3,520 shares Expires 2031-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,520 | $160.00 | $563,200.00 |
DisclosureSEC source: 0001415889-23-006300 · form4-04052023_050401.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,377 Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 3,520 | $105.92 | $372,838.40 |
DisclosureSEC source: 0001415889-23-006300 · form4-04052023_050401.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 805 | $153.38 | $123,470.90 |
DisclosureSEC source: 0001415889-23-003855 · form4-03022023_100358.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,377 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.36 to $153.43, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 11,330 | $153.06 | $1,734,169.80 |
DisclosureSEC source: 0001415889-23-003855 · form4-03022023_100358.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,182 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 9,656 | $154.28 | $1,489,727.68 |
DisclosureSEC source: 0001415889-23-003855 · form4-03022023_100358.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,512 Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 7,364 | $93.50 Strike: $93.50 | $688,534.00 |
DisclosureSEC source: 0001415889-23-003007 · form4-02222023_050201.xml · derivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,364 shares Expires 2033-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,933 | $151.29 | $595,023.57 |
DisclosureSEC source: 0001415889-23-003007 · form4-02222023_050201.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,168 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.49, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,431 | $150.73 | $517,154.63 |
DisclosureSEC source: 0001415889-23-003007 · form4-02222023_050201.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,101 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,364 | $93.50 | $688,534.00 |
DisclosureSEC source: 0001415889-23-003007 · form4-02222023_050201.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 21,944 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · derivative · entry 5 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,944 Underlying: Common Stock · 21,944 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,168 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,322 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 3,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,182 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 14,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002943 · form4-02212023_110239.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,814 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.